<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c64708k.txt
<TEXT>
                                 UNITED STATES
                        SECURITIES AND EXCHANGE COMMISION

                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT
                     Pursuant to Section 13 or 15 (d) of the
                         Securities Exchange Act of 1934
         Date of Report ( Date of earliest event reported): May 10, 2007


                              Global Biotech Corp.

               (Exact name registrant as specified in its charter)


                                    Delaware
                  (State or other jurisdiction of incorporation


                                   98-0229951
           (Commission file no.)      (IRS Employer Identification No.)

                            3810 St. Patrick Suite 2D
                                Montreal, Quebec
                                     H4E 1A4
              (Address of principal executive offices and zip code)


         Company's telephone number, including area code: (514) 935-8589


<PAGE>

Item 4.01 Change in Registrant's Certifying Accountant

     (a)  Previous Independent Accountants

          (i) Effective May 10, 2007 - Armando C. Ibarra ("Ibarra"), Certified
Public Accountant, resigned as the independent certified accountant of Global
Biotech Corp. (the "registrant").
.
          (ii) Ibarra's report on the Registrant's financial statements for the
past fiscal year ended November 30, 2005 did not contain an adverse opinion or a
disclaimer of opinion, and was not qualified as to uncertainty, audit scope, or
accounting principles. The report was modified to include an explanatory
paragraph wherein Ibarra expressed substantial doubt about the Registrant's
ability to continue as a going concern.

         (iii) The change of independent accountants was approved by the
               registrant's Board of Directors on May 10, 2007.
         (iv)  During the Registrant's fiscal year ended November 30, 2005,
               there were no disagreements on any matter of accounting
               principles, practices, financial statement disclosure, or
               auditing scope or procedures, which disagreements if not resolved
               to their satisfaction would have caused them to make reference in
               connection with their opinion to the subject matter of the
               disagreement.
         (v)   During the Registrant's fiscal year ended November 30, 2005,
               Ibarra did not advice the Registrant of any matters identified in
               paragraph (a)(l)(v) of Item 304 of Regulation S-K.
         (vi)  The Registrant requested Ibarra to furnish a letter addressed to
               the SEC, stating whether it agrees with the statement made by the
               Registrant and, if not, stating the respect in which it doest not
               agree.


     (b)  New Independent Accountants

          On May 10, 2007, the Registrant engaged Chang G. Park, CPA as its
principle accountant to audit the Registrant's financial statements. The
registrant did not consult Park on any matters described in paragraph (a)(2)(i)
or item 304 of Regulation S-K during the Registrant two most recent fiscal
years.

<PAGE>

Item 9.01 Exhibits

Exhibits 16.1 Letter dated June 4, 2007 from Armando C. Ibarra, Certified Public
Accountant


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: June 4, 2007

Global Biotech Corp.
By:/s/ Louis Greco
Name Louis Greco
Its: President & Acting Principal Financial Officer
</TEXT>
</DOCUMENT>